Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease [1]

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1459-1460

  Laske, Christoph ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; PLACEBO; SOLANEZUMAB; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BIOACCUMULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; LETTER; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE;

EID: 84898713444     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402193     Document Type: Letter

References (3)

1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33.
2. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21.
3. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44.